Bionics-AI is transforming the biotech landscape by integrating AI, ethnobotany, and molecular science to unlock novel therapeutics from natural biodiversity. As CEO, I lead efforts to develop an AI-native platform accelerating the discovery of small molecules targeting diseases like cancer and diabetes. With over a decade of experience in pharmaceutical R&D, biochemistry, and regulatory operations, my mission is to drive innovation in drug discovery while fostering global partnerships and collaborations.
Previously, at Eurofins, I spearheaded strategic initiatives that positioned the company as a technical and commercial benchmark in Peru, enhancing service delivery and regulatory compliance. My work bridges scientific exploration with operational excellence, aiming to deliver clinically validated, scalable solutions in the biotech sector. Currently, I focus on expanding Bionics-AI's platform and pipeline while cultivating alliances with scientific and pharma partners.More...